Henan Cancer Hospital
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1977-01-01
- Employees
- -
- Market Cap
- -
Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma（ESCC）.
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2019-08-21
- Last Posted Date
- 2021-08-24
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 47
- Registration Number
- NCT04063683
- Locations
- 🇨🇳
First Affiliated Hospital of Henan University of Science and Technolog, Luoyan, Henan, China
🇨🇳Henan cancer hospital, Zhengzhou, Henan, China
🇨🇳ANYANG Cancer Hospital, Anyang, Henan, China
Sintilimab Combined With Anlotinib as Second or Further-line Therapy for ED-SCLC
- First Posted Date
- 2019-08-14
- Last Posted Date
- 2023-06-28
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 42
- Registration Number
- NCT04055792
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
Study of CT and MR in the Lung Cancer
- First Posted Date
- 2019-07-26
- Last Posted Date
- 2020-04-01
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 400
- Registration Number
- NCT04034667
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, China
Study of CT and MR in the Gastric Cancer
- First Posted Date
- 2019-07-22
- Last Posted Date
- 2020-04-01
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 400
- Registration Number
- NCT04028375
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, China
Teripalimab Plus Chemotherapy in Local Advanced Esophageal Cancer
- First Posted Date
- 2019-06-14
- Last Posted Date
- 2019-12-12
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT03985670
- Locations
- 🇨🇳
Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China
Apatinib Plus SHR1210 in Advanced Mucosal Melanoma
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2019-06-14
- Last Posted Date
- 2019-06-14
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT03986515
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
Study of Sintlimab Maintenance Therapy in Patients With Extensive Small Cell Lung Cancer
- First Posted Date
- 2019-06-12
- Last Posted Date
- 2020-06-11
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT03983759
- Locations
- 🇨🇳
Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China
Treatment of Advanced Gastrointestinal Tumors With Albumin Taxol
- First Posted Date
- 2019-06-06
- Last Posted Date
- 2019-06-06
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT03977077
- Locations
- 🇨🇳
Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China
Clinical Study on the Second-line and Above Treatment of Advanced Solid Tumor With Anlotinib Combined With Pd-1 Antibody
- First Posted Date
- 2019-06-05
- Last Posted Date
- 2019-06-05
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT03975036
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
Etoposide/Cisplatin Compared With Irinotecan/Cisplatin for Advanced Gastrointestinal Neuroendocrine Tumor G3 Type
- First Posted Date
- 2019-05-24
- Last Posted Date
- 2019-05-24
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 112
- Registration Number
- NCT03963193
© Copyright 2024. All Rights Reserved by MedPath